瘤中的免疫细胞软组织肉瘤的微环境
Enar Jumaniyazova1, Anastasiya Lokhonina1,2,3, Dzhuliia Dzhalilova1,2
1Research Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, 117198 Moscow, Russia.
Cancers
|December 23, 2023
概括
软组织肉瘤 (STSs) 是一种具有攻击性的癌症,由于复杂的瘤-免疫细胞相互作用,其治疗反应不佳. 了解这些相互作用可以揭示生物标志物,并预测免疫治疗的有效性,以改善患者分层.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 软组织肉瘤 (STS) 是一种罕见的,具有有限治疗选择的侵袭性癌症.
- 瘤微环境,包括免疫细胞,在STS进展和治疗耐药性方面发挥着关键作用.
- STS的高度异质性使新型治疗策略的评估变得复杂.
研究的目的:
- 研究STS微环境中的瘤细胞和免疫细胞之间的复杂相互作用.
- 识别潜在的生物标志物,以预测STS中的治疗反应.
- 加强对软组织肉瘤的有效免疫疗法的开发.
主要方法:
- 在STS微环境中分析瘤细胞和免疫细胞之间的动态相互作用.
- 探索免疫细胞成分在STS进展和对治疗的抵抗中的作用.
- 对预测免疫治疗反应的潜在生物标志物的评估.
主要成果:
- 瘤微环境中的复杂相互作用有助于STSs的攻击性.
- 瘤-免疫细胞动态影响对传统抗瘤疗法的耐药性.
- 确定关键的免疫细胞作用可能会导致新的治疗点.
结论:
- 了解免疫微环境对于破译STS病原和攻击性行为至关重要.
- 免疫细胞分析可以帮助预测患者对免疫疗法的反应.
- 这项研究为个性化治疗策略和STS患者改善结果铺平了道路.
相关概念视频
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:19Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
02:40Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
02:30Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K